MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone972-8932-4010
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.40 million
Profitability
Miscellaneous
Employees73
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) announced its earnings results on Tuesday, May, 21st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The biopharmaceutical company earned $0.46 million during the quarter, compared to the consensus estimate of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
2 brokers have issued 12-month target prices for Mediwound's shares. Their predictions range from $11.00 to $15.00. On average, they expect Mediwound's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 247.6% from the stock's current price. View Analyst Price Targets for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.
Has Mediwound been receiving favorable news coverage?
Media stories about MDWD stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mediwound earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Mediwound.
Are investors shorting Mediwound?
Mediwound saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 112,600 shares, a drop of 28.4% from the April 15th total of 157,300 shares. Based on an average trading volume of 101,400 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the shares of the company are sold short. View Mediwound's Current Options Chain.
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Chromadex (CDXC), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Natural Alternatives International (NAII), True Drinks (TRUU), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), GLG Life Tech (GLGLF), FitLife Brands (FTLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).
What other stocks do shareholders of Mediwound own?
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 46)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
- Dr. Ety Klinger, Chief R&D Officer (Age 57)
Who are Mediwound's major shareholders?
Mediwound's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Meitav Dash Investments Ltd. (2.20%), Menta Capital LLC (0.16%), Oppenheimer & Co. Inc. (0.12%), Delek Group Ltd. (0.10%) and Marshall Wace LLP (0.07%).
Which major investors are buying Mediwound stock?
MDWD stock was bought by a variety of institutional investors in the last quarter, including Menta Capital LLC, Delek Group Ltd., Marshall Wace LLP, Meitav Dash Investments Ltd. and Oppenheimer & Co. Inc..
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $3.74.
How big of a company is Mediwound?
Mediwound has a market capitalization of $101.65 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.
What is Mediwound's official website?
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
